Full Breakdown
ETH Zurich’s “Compound 10” Shows Promise in Slowing Alzheimer’s Disease in Mice
6/8/2026, 7:53:33 PM
Breakthrough Targeting of GRK2 Aggregation
Researchers at ETH Zurich, led by Professor Ursula Quitterer, have created a small molecule called “Compound 10” that blocks aggregation of an inactive form of the enzyme G protein-coupled receptor kinase 2 (GRK2). The project originated from tissue samples obtained two decades ago at Ain Shams University Hospital in Cairo and was recently reported in *Cell Reports Medicine*. In aged mouse models of Alzheimer’s disease, the compound preserves mitochondrial pores, reduces amyloid-beta buildup, and extends neuronal survival.
Scientific Background: GRK2 in Dementia
About two decades of analysis of brain tissue from patients at Ain Shams University Hospital in Cairo revealed that dementia brains contain high levels of an inactivated GRK2 variant. This variant forms aggregates that attach to mitochondrial membranes, block pores, and trigger energy deficits that promote amyloid-beta production, creating a self-reinforcing cycle of neuronal stress.
Data from Mouse Models
In mice treated with Compound 10, GRK2 aggregation was markedly reduced, mitochondrial function recovered, and amyloid-beta deposition fell. Compared with untreated controls, the treated group lived longer, showed delayed neurodegeneration, exhibited better cardiac performance, and displayed fewer grey hairs in old age.
Potential Impact on Alzheimer’s Therapeutics
Existing Alzheimer’s drugs only modestly delay disease progression. By intervening upstream—preserving mitochondrial energy and limiting amyloid-beta formation—Compound 10 offers a mechanistically distinct approach that could complement current therapies and improve patient quality of life if human trials confirm efficacy.
Official Statements & Responses
ETH Zurich researchers stress that identifying GRK2 as a druggable target expands therapeutic options beyond amyloid-beta-centric strategies. They emphasize the need for industrial partnership to move Compound 10 through pharmacological optimization, safety assessment, and clinical testing.
Criticism & Limitations
The findings are limited to animal models; human efficacy and safety remain untested. Mouse experiments required 18–24 months per cycle, illustrating the slow pace of Alzheimer’s research. Commercial development also depends on securing a partner and completing regulatory steps.
Verbatim Quotes
- “It took so long simply because everything takes so long in Alzheimer's research," explains Quitterer.” — Ursula Quitterer, ETH Zurich
- “Alzheimer's is a very complex disease," says Quitterer.” — Ursula Quitterer, ETH Zurich
- “Current medications do not cure the disease, but rather – at most – delay its progression by several months.” — Ursula Quitterer, ETH Zurich
- “Now, Quitterer and ETH Zurich are looking for a company that is interested in taking the next steps towards developing a drug.” — News report quoting Ursula Quitterer
What’s Next
The team has filed a patent for Compound 10 and is seeking industrial partners to launch pre-clinical development, followed by phased clinical trials. Successful translation would establish GRK2 inhibition as a new pillar in Alzheimer’s disease management.
